380 related articles for article (PubMed ID: 27999056)
21. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
[TBL] [Abstract][Full Text] [Related]
22. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R; Roberts J; Martin-Carpenter L; Zala C
Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
24. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
25. Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.
Negredo E; Bonjoch A; Puig J; Echeverría P; Estany C; Santos JR; Moltó J; Pérez-Álvarez N; Ornelas A; Clotet B
New Microbiol; 2015 Apr; 38(2):193-9. PubMed ID: 25938744
[TBL] [Abstract][Full Text] [Related]
26. Second-Line Switch to Dolutegravir for Treatment of HIV Infection.
Ombajo LA; Penner J; Nkuranga J; Mecha J; Mburu M; Odhiambo C; Ndinya F; Aksam R; Njenga R; Wahome S; Muiruri P; Eshiwani S; Kimani M; Ngugi C; Pozniak A
N Engl J Med; 2023 Jun; 388(25):2349-2359. PubMed ID: 37342923
[TBL] [Abstract][Full Text] [Related]
27. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
29. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
[TBL] [Abstract][Full Text] [Related]
30. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Walmsley S; Baumgarten A; Berenguer J; Felizarta F; Florence E; Khuong-Josses MA; Kilby JM; Lutz T; Podzamczer D; Portilla J; Roth N; Wong D; Granier C; Wynne B; Pappa K
J Acquir Immune Defic Syndr; 2015 Dec; 70(5):515-9. PubMed ID: 26262777
[TBL] [Abstract][Full Text] [Related]
31. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
[TBL] [Abstract][Full Text] [Related]
32. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
33. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
[TBL] [Abstract][Full Text] [Related]
35. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Nishijima T; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2012 Mar; 26(5):649-51. PubMed ID: 22233654
[TBL] [Abstract][Full Text] [Related]
37. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
Llibre JM; Cozzi-Lepri A; Pedersen C; Ristola M; Losso M; Mocroft A; Mitsura V; Falconer K; Maltez F; Beniowski M; Vullo V; Hassoun G; Kuzovatova E; Szlavik J; Kuznetsova A; Stellbrink HJ; Duvivier C; Edwards S; Laut K; Paredes R;
Medicine (Baltimore); 2016 Oct; 95(40):e5020. PubMed ID: 27749561
[TBL] [Abstract][Full Text] [Related]
38. Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Ciccullo A; D'Avino A; Lassandro AP; Baldin G; Borghetti A; Dusina A; Emiliozzi A; Gagliardini R; Moschese D; Belmonti S; Lombardi F; Di Giambenedetto S
Infez Med; 2018 Dec; 26(4):336-340. PubMed ID: 30555137
[TBL] [Abstract][Full Text] [Related]
39. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients.
Calza L; Colangeli V; Borderi M; Coladonato S; Tazza B; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2019 Mar; 74(3):731-738. PubMed ID: 30541118
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
